Bioretec Oy

DB:0TN Stock Report

Market Cap: €37.8m

Bioretec Oy Valuation

Is 0TN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0TN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0TN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0TN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0TN?

Key metric: As 0TN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0TN. This is calculated by dividing 0TN's market cap by their current book value.
What is 0TN's PB Ratio?
PB Ration/a
Book€0
Market Cap€37.83m

Price to Book Ratio vs Peers

How does 0TN's PB Ratio compare to its peers?

The above table shows the PB ratio for 0TN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.3x
AAQ1 aap Implantate
1.6xn/a€22.4m
NN6 NanoRepro
0.5xn/a€19.6m
GME Geratherm Medical
0.7x89.5%€15.0m
PUS PULSION Medical Systems
6.5xn/a€134.4m
0TN Bioretec Oy
n/an/a€37.8m

Price-To-Book vs Peers: Insufficient data to calculate 0TN's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does 0TN's PB Ratio compare vs other companies in the DE Medical Equipment Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
0TN is unprofitableIndustry Avg. 2.2xNo. of Companies4PB012345+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: Insufficient data to calculate 0TN's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is 0TN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0TN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0TN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0TN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.84
€3.55
+93.5%
32.4%€4.70€2.40n/a2
Nov ’25€1.80
€3.65
+103.3%
28.8%€4.70€2.60n/a2
Oct ’25€2.67
€3.85
+44.2%
22.1%€4.70€3.00n/a2
Sep ’25€2.74
€3.85
+40.5%
22.1%€4.70€3.00n/a2
Aug ’25€2.75
€3.85
+40.0%
22.1%€4.70€3.00n/a2
Jul ’25€2.78
€3.85
+38.5%
22.1%€4.70€3.00n/a2
Jun ’25€2.51
€3.85
+53.4%
22.1%€4.70€3.00n/a2
May ’25€2.49
€3.75
+50.6%
25.3%€4.70€2.80n/a2
Apr ’25€2.61
€3.75
+43.7%
25.3%€4.70€2.80n/a2
Mar ’25€2.19
€3.75
+71.2%
25.3%€4.70€2.80n/a2
Feb ’25€2.25
€3.75
+66.7%
25.3%€4.70€2.80n/a2
Jan ’25€2.30
€3.75
+63.0%
25.3%€4.70€2.80n/a2
Dec ’24€2.17
€3.80
+75.1%
23.7%€4.70€2.90n/a2
Nov ’24€2.43
€3.80
+56.4%
23.7%€4.70€2.90€1.802
Oct ’24€2.62
€3.80
+45.0%
23.7%€4.70€2.90€2.672
Sep ’24€2.32
€3.80
+63.8%
23.7%€4.70€2.90€2.742
Aug ’24€2.37
€3.70
+56.1%
27.0%€4.70€2.70€2.752
Jul ’24€2.37
€3.70
+56.1%
27.0%€4.70€2.70€2.782
Jun ’24€2.31
€3.70
+60.2%
27.0%€4.70€2.70€2.512
May ’24€2.35
€3.55
+51.1%
32.4%€4.70€2.40€2.492
Apr ’24€2.97
€3.55
+19.5%
32.4%€4.70€2.40€2.612
Mar ’24€2.40
€1.85
-22.9%
18.9%€2.20€1.50€2.192
Feb ’24€2.14
€1.85
-13.6%
18.9%€2.20€1.50€2.252
Jan ’24€1.33
€1.85
+39.1%
18.9%€2.20€1.50€2.302
Dec ’23€1.37
€1.85
+35.5%
18.9%€2.20€1.50€2.172
Nov ’23€1.43
€1.85
+29.4%
18.9%€2.20€1.50€2.432

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.0%

1Y

-38.8%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.1%

1Y

16.0%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%